The Role of Yes Activated Protein (YAP) in Melanoma Metastasis

Overview

Journal iScience

Publisher Cell Press

Date 2024 May 21

PMID 38770136

Authors

Andrew Leask

John Nguyen

Angha Naik

Pratyusha Chitturi

Bruce L Riser

Affiliations

Soon will be listed here.

Abstract

Hippo was first identified in a genetic screen as a protein that suppressed proliferation and cell growth. Subsequently, it was shown that hippo acted in a so-called canonical cascade to suppress Yorkie, the Drosophila equivalent of Yes-activated protein (YAP), a mechanosensitive transcriptional cofactor that enhances the activity of the TEAD family of transcription factors. YAP promotes fibrosis, activation of cancer-associated fibroblasts, angiogenesis and cancer cell invasion. YAP activates the expression of the matricellular proteins CCN1 (cyr61) and CCN2 (ctgf), themselves mediators of fibrogenesis and oncogenesis, and coordination of matrix deposition and angiogenesis. This review discusses how therapeutically targeting YAP through YAP inhibitors verteporfin and celastrol and its downstream mediators CCN1 and CCN2 might be useful in treating melanoma.

Citing Articles

Acral Melanoma: A Review of Its Pathogenesis, Progression, and Management.

Kim S, Tsao H Biomolecules. 2025; 15(1).

PMID: 39858514 PMC: 11763010. DOI: 10.3390/biom15010120.

YAP/TAZ Signalling Controls Epidermal Keratinocyte Fate.

Pankratova M, Riabinin A, Butova E, Selivanovskiy A, Morgun E, Ulianov S Int J Mol Sci. 2024; 25(23).

PMID: 39684613 PMC: 11641583. DOI: 10.3390/ijms252312903.

YAP enhances mitochondrial OXPHOS in tumor-infiltrating Treg through upregulating Lars2 on stiff matrix.

Bai J, Yan M, Xu Y, Wang Y, Yao Y, Jin P J Immunother Cancer. 2024; 12(11).

PMID: 39551603 PMC: 11574482. DOI: 10.1136/jitc-2024-010463.

References

Fisher M, Grun D, Adhikary G, Xu W, Eckert R . Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells. Oncotarget. 2018; 8(66):110257-110272. PMC: 5746380. DOI: 10.18632/oncotarget.22628. View

Harvey K, Pfleger C, Hariharan I . The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003; 114(4):457-67. DOI: 10.1016/s0092-8674(03)00557-9. View

Kim J, Finlay G, Baguley B . The role of the hippo pathway in melanocytes and melanoma. Front Oncol. 2013; 3:123. PMC: 3655322. DOI: 10.3389/fonc.2013.00123. View

Liu S, Shi-Wen X, Abraham D, Leask A . CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum. 2010; 63(1):239-46. DOI: 10.1002/art.30074. View

Busetti A, Soncin M, Jori G, Rodgers M . High efficiency of benzoporphyrin derivative in the photodynamic therapy of pigmented malignant melanoma. Br J Cancer. 1999; 79(5-6):821-4. PMC: 2362652. DOI: 10.1038/sj.bjc.6690131. View

Maity G, Ghosh A, Gupta V, Haque I, Sarkar S, Das A . CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2019; 18(4):788-800. DOI: 10.1158/1535-7163.MCT-18-0899. View

Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V . Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol. 2013; 134(1):123-132. PMC: 3938155. DOI: 10.1038/jid.2013.319. View

Harvey K, Tapon N . The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer. 2007; 7(3):182-91. DOI: 10.1038/nrc2070. View

Tao W, Zhang S, Turenchalk G, Stewart R, St John M, Chen W . Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat Genet. 1999; 21(2):177-81. DOI: 10.1038/5960. View

10.

Abbas S, Bhoumik A, Dahl R, Vasile S, Krajewski S, Cosford N . Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res. 2007; 13(22 Pt 1):6769-78. PMC: 2874065. DOI: 10.1158/1078-0432.CCR-07-1536. View

11.

Leask A . Conjunction junction, what's the function? CCN proteins as targets in fibrosis and cancers. Am J Physiol Cell Physiol. 2020; 318(6):C1046-C1054. PMC: 7311738. DOI: 10.1152/ajpcell.00028.2020. View

12.

Felley-Bosco E, Stahel R . Hippo/YAP pathway for targeted therapy. Transl Lung Cancer Res. 2015; 3(2):75-83. PMC: 4367659. DOI: 10.3978/j.issn.2218-6751.2014.02.03. View

13.

Ferretti L, Bohi F, Leslie Pedrioli D, Cheng P, Ferrari E, Baumgaertner P . Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma. Cancer Res. 2023; 83(23):3974-3988. DOI: 10.1158/0008-5472.CAN-23-0485. View

14.

Bennett D . Ultraviolet wavebands and melanoma initiation. Pigment Cell Melanoma Res. 2008; 21(5):520-4. DOI: 10.1111/j.1755-148X.2008.00500.x. View

15.

Wei X, Shimizu T, Lai Z . Mob as tumor suppressor is activated by Hippo kinase for growth inhibition in Drosophila. EMBO J. 2007; 26(7):1772-81. PMC: 1847660. DOI: 10.1038/sj.emboj.7601630. View

16.

Sudol M, Bork P, Einbond A, Kastury K, Druck T, Negrini M . Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem. 1995; 270(24):14733-41. DOI: 10.1074/jbc.270.24.14733. View

17.

Siskind V, Aitken J, Green A, Martin N . Sun exposure and interaction with family history in risk of melanoma, Queensland, Australia. Int J Cancer. 2002; 97(1):90-5. DOI: 10.1002/ijc.1563. View

18.

Diazzi S, Baeri A, Fassy J, Lecacheur M, Marin-Bejar O, Girard C . Blockade of the pro-fibrotic reaction mediated by the miR-143/-145 cluster enhances the responses to targeted therapy in melanoma. EMBO Mol Med. 2022; 14(3):e15295. PMC: 8899916. DOI: 10.15252/emmm.202115295. View

19.

Zhang H, Pasolli H, Fuchs E . Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc Natl Acad Sci U S A. 2011; 108(6):2270-5. PMC: 3038759. DOI: 10.1073/pnas.1019603108. View

20.

Widmer D, Cheng P, Eichhoff O, Belloni B, Zipser M, Schlegel N . Systematic classification of melanoma cells by phenotype-specific gene expression mapping. Pigment Cell Melanoma Res. 2012; 25(3):343-53. DOI: 10.1111/j.1755-148X.2012.00986.x. View